Uncategorized
ThromboGenics to evaluate Jetrea for retinal vein occlusion
ThromboGenics has started to evaluate Jetrea as a potential treatment for retinal vein occlusion, according to a press release.The research will be derived from previously collected phase 2a data that noted Jetrea (ocriplasmin) may potentially treat peripheral arterial occlusions, focusing on its potential to lyse blood clots in retinal veins, the release said.